Affiliation:
1. Department of Pharmacology, Therapeutics and Toxicology , Faculty of Basic Medical Sciences, College of Medicine, University of Lagos , Lagos , Nigeria
Abstract
Abstract
Objectives
Early diagnosis and management of known cardiovascular disease risk attributes such as hypertension lessens morbidity and mortality as well as increase quality of life of patients. This present study was modelled to investigate the ameliorative effect of Kolaviron, an extract of Garcinia kola Heckel seeds, in ethanol- and sucrose-induced hypertension.
Methods
Test animals were divided into six groups of six animals each for each hypertensive model. Animals were treated daily with distilled water (10 ml/kg); 35% ethanol (3 g/kg) or sucrose (5–7%); Kolaviron (50, 100 and 200 mg/kg) separately plus ethanol or sucrose and Amlodipine (0.14 mg/kg) separately plus ethanol or sucrose for 8 weeks. Systolic, diastolic and mean arterial pressures were determined using non-invasive BP system after 8 weeks. Blood was obtained for the assessment of biochemical parameters, lipid profile and antioxidant indices. Vital organs were collected for approximation of tissue antioxidant levels.
Results
Results show that Kolaviron at various doses and Amlodipine significantly reduced (p<0.05–0.001) the elevated systolic, diastolic, and mean arterial pressures produced by ethanol and sucrose administration. Additionally, Kolaviron and Amlodipine significantly overturned (p<0.05–0.001) the reduction in GSH, SOD and CAT, and elevation in MDA levels elicited by ethanol and sucrose. Furthermore, Kolaviron and Amlodipine produced significant reduction (p<0.001) in levels of cholesterol, triglycerides and low-density lipoproteins, as well as significant increase (p<0.01–0.001) in levels of high-density lipoproteins.
Conclusions
Results from this study demonstrate that Kolaviron possibly possesses significant antihypertensive effect which may possibly be attributed to its antioxidant effects and relative improvement of lipid profile.
Subject
Complementary and alternative medicine
Reference48 articles.
1. World Health Organization. World Health Organisation key facts on cardiovascular diseases (CVDs). WHO Fact Sheets; 2017. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2. World Health Organization. A global brief on hypertension: silent killer. Geneva: Global Health Crises; 2013.
3. Lim, SS, Vos, T, Flaxman, AD, Danaei, G, Shibuya, K, Adair-Rohani, H, et al.. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224–60. https://doi.org/10.1016/S0140-6736(12)61766-8.
4. James, PA, Oparil, S, Carter, BL, Cushman, WC, Dennison-Himmelfarb, C, Handler, J, et al.. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20. https://doi.org/10.1001/jama.2013.284427.
5. Lewington, S, Clarke, R, Qizilbash, N, Collins, R, Peto, R. Age-specific relevance of blood pressure to vascular disease in one million people in 61 cohort studies. Prospective Studies Collaboration. Lancet 2002;360:1903–13.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献